Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes

MLA

Cortellini, A., et al. Osimertinib beyond Disease Progression in T790M EGFR-Positive NSCLC Patients: A Multicenter Study of Clinicians’ Attitudes. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1415733624&authtype=sso&custid=ns315887.

APA

Cortellini, A., Leonetti, A., Catino, A., Pizzutillo, P., Ricciuti, B., De Giglio, A., Chiari, R., Bordi, P., Santini, D., Giusti, R., De Tursi, M., Brocco, D., Zoratto, F., Rastelli, F., Citarella, F., Russano, M., Filetti, M., Marchetti, P., Berardi, R., … Tiseo M. (2020). Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes.

Chicago

Cortellini, A, A Leonetti, A Catino, P Pizzutillo, B Ricciuti, A De Giglio, R Chiari, et al. 2020. “Osimertinib beyond Disease Progression in T790M EGFR-Positive NSCLC Patients: A Multicenter Study of Clinicians’ Attitudes.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1415733624&authtype=sso&custid=ns315887.